P2.13-27 Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients With EGFR Mutant NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1422
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.13-16 Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-55 Unique Genetic Profiles From Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC With Leptomeningeal Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-19 Prognostic Value Inferred From the Quantitative Measurement of EGFR Mutation Using PNA-Clamping Method in Advanced EGFR Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients With Brain Metastases From EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

Scientific Reports
Multidisciplinary
2017English

Development and Validation of a Simple Risk Score to Predict 30-Day Readmission After Percutaneous Coronary Intervention in a Cohort of Medicare Patients

Catheterization and Cardiovascular Interventions
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2016English

External Validation of a Risk Score to Predict Severe Posthepatectomy Biliary Leakage

HPB
HepatologyGastroenterology
2018English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy